PRQR · ProQR Therapeutics N.V.
Market Cap
$292.12M
Shares
141.12M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
15.91M
-15.9%
FY2025
Net Income
-42.18M
-51.9%
FY2025
Operating Margin
-273.14%
-112pp
FY2025
Operating Cash Flow
-52.79M
-45.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EUR | 15.91M | 18.91M | 6.51M | 3.59M | 1.34M | — | — | — | — | — | — |
| EUR | 44.73M | 36.36M | 25.15M | 50.87M | 42.22M | 38.14M | 46.49M | 29.51M | 31.15M | 31.92M | 23.4M |
| EUR | 15.06M | 13.66M | 16.24M | 18.65M | 17.37M | 13.69M | 12.89M | 12.54M | 10.84M | 9.48M | 6.84M |
| EUR | 2.7M | 2.76M | 2.51M | 2.52M | 2.33M | 2.36M | 2.05M | 992K | — | — | — |
| EUR | -43.45M | -30.47M | -31.86M | -65.16M | -57.21M | -42.37M | -57.45M | -36.29M | -40.5M | -39.57M | -27M |
| EUR | 1.29M | 1.08M | 1.46M | 5.13M | 3.41M | 4.03M | 1.08M | — | — | — | — |
| EUR | -42.17M | -27.96M | -27.81M | -64.11M | -60.68M | -46.49M | -56.61M | -37.09M | -43.67M | -39.1M | -20.83M |
| EUR | -42.18M | -27.76M | -28.12M | -64.42M | -60.74M | -46.57M | -56.48M | -36.89M | -43.64M | -39.1M | -20.83M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
No verified debt profile is available yet. This does not establish that the company has no debt or covenants.
Key facts
CIK
1612940
CUSIP
N71542109
13F (30d)
48 filings
48 filers
Visit website
Investor relations